442 reports of this reaction
1.6% of all ACLIDINIUM BROMIDE reports
#13 most reported adverse reaction
OBSTRUCTIVE AIRWAYS DISORDER is the #13 most commonly reported adverse reaction for ACLIDINIUM BROMIDE, manufactured by Covis Pharma US, Inc. There are 442 FDA adverse event reports linking ACLIDINIUM BROMIDE to OBSTRUCTIVE AIRWAYS DISORDER. This represents approximately 1.6% of all 27,417 adverse event reports for this drug.
Patients taking ACLIDINIUM BROMIDE who experience obstructive airways disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OBSTRUCTIVE AIRWAYS DISORDER is a less commonly reported adverse event for ACLIDINIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to obstructive airways disorder, the following adverse reactions have been reported for ACLIDINIUM BROMIDE:
The following drugs have also been linked to obstructive airways disorder in FDA adverse event reports:
OBSTRUCTIVE AIRWAYS DISORDER has been reported as an adverse event in 442 FDA reports for ACLIDINIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OBSTRUCTIVE AIRWAYS DISORDER accounts for approximately 1.6% of all adverse event reports for ACLIDINIUM BROMIDE, making it a notable side effect.
If you experience obstructive airways disorder while taking ACLIDINIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.